Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13205156 | 1.00 | PPARA (0.57) | PPARASYKCTSSCTSKPPARG | |
| SCHEMBL1094803 | 1.00 | PPARA (0.57) | PPARASYKCTSSCTSKPPARG | |
| SCHEMBL953788 | 0.93 | PPARA (0.55) | PPARASYKCTSSCTSKPPARG | |
| SCHEMBL3906191 | 0.93 | PPARA (0.55) | PPARASYKCTSSCTSKPPARG | |
| SCHEMBL693646 | 0.93 | PPARA (0.55) | PPARASYKCTSSCTSKPPARG | |
| SCHEMBL8615707 | 0.91 | KLK7 (0.54) | PPARASYKCTSSCTSKKLK7 | |
| SCHEMBL5970352 | 0.91 | KLK7 (0.54) | PPARASYKCTSSCTSKKLK7 | |
| Alcohol SCHEMBL692835 | 0.90 | CTSK (0.55) | PPARASYKCTSSCTSKKLK7 | |
| SCHEMBL995705 | 0.90 | SYK (0.57) | PPARASYKCTSSCTSKCTSL | |
| SCHEMBL22433357 | 0.90 | PPARA (0.57) | PPARASYKCTSSCTSKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025060884-A1 | SIRNAS FOR SIMULTANEOUSLY INHIBITING EXPRESSION OF TWO TARGET GENES, DRUG AND USE THEREOF | 广州必贝特医药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2022-10-13 | — | — | US | disclosed |
| CN-112457218-B | Synthesis method of 2, 4-diaminobutyric acid derivative | 宁夏医科大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-113710687-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-112457218-A | Synthesis method of 2, 4-diaminobutyric acid derivative | 宁夏医科大学 | 2021-03-09 | — | — | CN | disclosed |
| WO-2020185999-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10711273-B2 | Amino acid-modified nucleic acid and utilization thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-07-14 | — | — | US | disclosed |
| CN-108602806-A | Improved Ai Palin peptides receptor (APJ) agonist and application thereof | 研究三角协会 | 2018-09-28 | — | — | CN | disclosed |
| US-8952031-B2 | Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| CN-1434795-A | Acylated Pseudodipeptides with Functionalized Auxiliary Branches | OM PHARMA (CH) | 2003-08-06 | — | — | CN | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| EP-0873123-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| EP-1244656-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1304402-A | Sulfonamide derivatives | SANKYO CO (JP) | 2001-07-18 | — | — | CN | disclosed |
| EP-1069110-A1 | SULFONAMIDE DERIVATIVES | Sankyo Company Limited (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | PPARA 4273/4885SYK 4686/4885CTSS 3234/4885 |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | PPARA 1161/4885SYK 1374/4885CTSS 1285/4885 |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, CCR10, SELPLG | PPARA 1012/4885SYK 1482/4885CTSS 1590/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | PPARA 4669/4885SYK 2361/4885CTSS 640/4885 |
| US-20220324907-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB3 | PPARA 4669/4885SYK 2361/4885CTSS 640/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | PPARA 771/4885SYK 1499/4885CTSS 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.